Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 31 results found. Search for [ U.S. Food and Drug Administration (FDA) ]

Results 1 to 21 of 31
PB Jayakumar
November 6, 2019
Most violations relate to rectifiable documentation, data maintenance, batch-wise consistent production quality, data on supply chain, stability issues, microbial contamination and quality checks


Reuters
October 19, 2019
The recall is the latest blow to the more than 130-year-old US healthcare conglomerate that is facing thousands of lawsuits over a variety of products, including baby powder, opioids, medical devices and the antipsychotic Risperdal.


Reuters
October 9, 2019
Analysts called the amount excessive, particularly since the plaintiff, Nicholas Murray, had already won $680,000 in compensatory damages over his claims


PTI
October 9, 2019



PTI
September 10, 2019



PTI
August 24, 2019



PTI
August 16, 2019



Reuters
July 17, 2019
The U.S. Food and Drug Administration (FDA) said it found adulteration and \"significant violations\" of current good manufacturing practice (CGMP) regulations at Strides Pharma Sciences Ltd's plant in Puducherry in south India.


PTI
June 28, 2019



PTI
June 20, 2019



PTI
May 21, 2019



PTI
May 3, 2019



PTI
March 15, 2019



E Kumar Sharma
February 28, 2019
India was very much of a transactional entity supporting high-end activities that were done elsewhere. That is not true anymore. For me, India is the largest global site that I have in my portfolio, says Badhri Srinivasan, Head Global Development Operations, Novartis.


Reuters
December 15, 2018
Asbestos that allegedly lurked in J&J's Baby Powder causes mesothelioma and is linked with ovarian and other cancers


PTI
November 21, 2018



PTI
October 31, 2018



E Kumar Sharma
New Delhi, June 13, 2018
The development is a hugely positive development both for Sun Pharma and for Indian pharma. From a sentiment perspective, it is significant given that the company has been finally able to get its facility cleared after three years.


E Kumar Sharma
New Delhi, November 12, 2017
Every business has the right to adopt legitimate practises to protect their own interest. Right? But a recent article argues that going beyond the patent act, which permits research and development during the life of a patent, some innovator drug companies are busy trying to block this.


E Kumar Sharma
New Delhi, October 11, 2017
Analysts see it as a good opportunity for Lupin but feel the company may need to wait for say another two years or so for benefits to accrue since they may first need to invest in certain things, putting additional pressure on the company.


PAGES 1 OF 2  12